Mepolizumab versus placebo for asthma. https://t.co/qM1lFRJ5t2
RT @pulmonology101: @CochraneAirways Mepolizumab versus placebo for asthma. https://t.co/IEFlMBIfnr #RespEd
RT @pulmonology101: @CochraneAirways Mepolizumab versus placebo for asthma. https://t.co/IEFlMBIfnr #RespEd
@CochraneAirways Mepolizumab versus placebo for asthma. https://t.co/IEFlMBIfnr #RespEd
Mepolizumab stops activation of those pesky eosinophils. But does it help asthma? Cochrane is cautious https://t.co/auTqPEk6tt
@CochraneAirways #Mepolizumab versus placebo for #asthma. 2015 review. http://t.co/CkSRWYy3fx #RespEd
[Cochrane] as usual... "It is not possible to draw firm conclusions". Mepolizumab versus placebo for asthma http://t.co/vIdEWYSVCm
Mepolizumab versus placebo for asthma. - PubMed - NCBI http://t.co/eCeEKSlY05
Mepolizumab versus placebo for asthma. - PubMed - NCBI http://t.co/eCeEKSlY05
New #Cochrane Review: Mepolizumab versus placebo for asthma http://t.co/cEI313km4G
New #Cochrane Review: Mepolizumab versus placebo for asthma http://t.co/cEI313km4G
New #Cochrane Review: Mepolizumab versus placebo for asthma http://t.co/cEI313km4G
#Rev_Sist #Cochrane #Mepolizumab vs placebo en #asma_crónico niños y adultos http://t.co/vYJJheCQHv @sefh_ @safh_info @SeparRespira @semfyc
#Rev_Sist #Cochrane #Mepolizumab vs placebo en #asma_crónico niños y adultos http://t.co/vYJJheCQHv @sefh_ @safh_info @SeparRespira @semfyc
Mepolizumab versus placebo for asthma. http://t.co/b0mfZofznS
New #Cochrane Review: Mepolizumab versus placebo for asthma http://t.co/cEI313km4G
Mepolizumab versus placebo for asthma. http://t.co/0KAiOouzWP
Further research must clarify subgroups of people who could benefit: also dosage, dosing regimens &treatment duration http://t.co/Lx3jyT0zgA
Heterogeneity in severity- from mild to moderate atopic asthma, to persistent &eosinophilic asthma w/recurrent exac. http://t.co/xiIKCVL6QS
7 studies involved IV mepolizumab; 1 had a subcutaneous arm. http://t.co/VRIe7yd4lL
8 studies on 1707 participants included. Only 2 studies included adolescents, but did not report separate findings http://t.co/ZBcbOTF3K4
Mepolizumab: a monoclonal antibody against IL-5 a cytokine which activates eosinophils, and cause airway inflammation http://t.co/qLumtRMdq0
New #Cochrane Review: Mepolizumab versus placebo for asthma http://t.co/cEI313km4G